• Sanna T Leinonen, Kristiina Aalto, Kaisu M Kotaniemi, and Tero T Kivelä.
• Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland. sanna.leinonen@hus.fi.
• Clin Exp Rheumatol. 2017 Nov 1; 35 (6): 1043-1046.

ObjectivesTo evaluate the association of adalimumab trough levels and anti-adalimumab antibodies with activity of uveitis in juvenile idiopathic arthritis-related uveitis.MethodsThis was a retrospective observational case series in a clinical setting at the Department of Ophthalmology, Helsinki University Hospital, Finland in 2014-2016. Thirty-one paediatric patients with chronic anterior juvenile idiopathic arthritis-related uveitis in 58 eyes and who had been on adalimumab ≥6 months were eligible for the study. Uveitis activity during adalimumab treatment, adalimumab trough levels and anti-adalimumab antibody levels were recorded.ResultsAnti-adalimumab antibody levels ≥12 AU /ml were detected in nine patients (29%). This level of anti-adalimumab antibodies was associated with a higher grade of uveitis (p<0.001), uveitis that was not in remission (p=0.001) and with lack of concomitant methotrexate therapy (p=0.043). In patients with anti-adalimumab antibody levels <12 AU/ml, higher serum trough levels did not associate with better control of uveitis (p=0.86).ConclusionsAdalimumab treatment might be better guided by monitoring anti-adalimumab antibody formation in treating JIA-related uveitis.

20 keywords...

hide…